380 related articles for article (PubMed ID: 28126303)
1. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2).
Mell LK; Sirák I; Wei L; Tarnawski R; Mahantshetty U; Yashar CM; McHale MT; Xu R; Honerkamp-Smith G; Carmona R; Wright M; Williamson CW; Kasaová L; Li N; Kry S; Michalski J; Bosch W; Straube W; Schwarz J; Lowenstein J; Jiang SB; Saenz CC; Plaxe S; Einck J; Khorprasert C; Koonings P; Harrison T; Shi M; Mundt AJ;
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):536-545. PubMed ID: 28126303
[TBL] [Abstract][Full Text] [Related]
2. Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III Trial.
Williamson CW; Sirák I; Xu R; Portelance L; Wei L; Tarnawski R; Mahantshetty U; Heide ES; Yashar CM; McHale MT; Bosch W; Lowenstein J; Saenz CC; Plaxe S; Eskander R; Einck J; Mundt AJ; Mayadev J; Mell LK
Int J Radiat Oncol Biol Phys; 2022 Jan; 112(1):169-178. PubMed ID: 34419564
[TBL] [Abstract][Full Text] [Related]
3. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
[TBL] [Abstract][Full Text] [Related]
4. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.
Liang Y; Bydder M; Yashar CM; Rose BS; Cornell M; Hoh CK; Lawson JD; Einck J; Saenz C; Fanta P; Mundt AJ; Bydder GM; Mell LK
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):406-14. PubMed ID: 22687195
[TBL] [Abstract][Full Text] [Related]
6. Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study.
Naik A; Gurjar OP; Gupta KL; Singh K; Nag P; Bhandari V
Cancer Radiother; 2016 Jul; 20(5):370-6. PubMed ID: 27368915
[TBL] [Abstract][Full Text] [Related]
7. Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin.
Simpson DR; Song WY; Moiseenko V; Rose BS; Yashar CM; Mundt AJ; Mell LK
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e81-6. PubMed ID: 22516388
[TBL] [Abstract][Full Text] [Related]
8. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study.
Gandhi AK; Sharma DN; Rath GK; Julka PK; Subramani V; Sharma S; Manigandan D; Laviraj MA; Kumar S; Thulkar S
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):542-8. PubMed ID: 24074927
[TBL] [Abstract][Full Text] [Related]
9. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.
Huang J; Gu F; Ji T; Zhao J; Li G
Radiat Oncol; 2020 Jul; 15(1):180. PubMed ID: 32727497
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.
Schefter TE; Winter K; Kwon JS; Stuhr K; Balaraj K; Yaremko BP; Small W; Gaffney DK
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1179-84. PubMed ID: 22342094
[TBL] [Abstract][Full Text] [Related]
12. Helical tomotherapy with simultaneous integrated boost after laparoscopic staging in patients with cervical cancer: analysis of feasibility and early toxicity.
Marnitz S; Köhler C; Burova E; Wlodarczyk W; Jahn U; Grün A; Budach V; Stromberger C
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e137-43. PubMed ID: 21600704
[TBL] [Abstract][Full Text] [Related]
13. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
14. Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy.
Hui B; Zhang Y; Shi F; Wang J; Wang T; Wang J; Yuan W; Li Y; Liu Z
Int J Gynecol Cancer; 2014 Nov; 24(9):1648-52. PubMed ID: 25275663
[TBL] [Abstract][Full Text] [Related]
15. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.
Klopp AH; Moughan J; Portelance L; Miller BE; Salehpour MR; Hildebrandt E; Nuanjing J; D'Souza D; Souhami L; Small W; Gaur R; Jhingran A
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):83-90. PubMed ID: 23582248
[TBL] [Abstract][Full Text] [Related]
16. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
[TBL] [Abstract][Full Text] [Related]
17. Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation.
Ho JC; Allen PK; Bhosale PR; Rauch GM; Fuller CD; Mohamed AS; Frumovitz M; Jhingran A; Klopp AH
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):546-553. PubMed ID: 28011045
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 Trial of Concurrent Gemcitabine and Cisplatin with Image Guided Intensity Modulated Radiation Therapy for Locoregionally Advanced Cervical Carcinoma.
Mell LK; Xu R; Yashar CM; McHale MT; Einck JP; Mayadev J; Lee E; Binder P; Rash D; Eskander R; Heide ES; Plaxe SC; Mundt AJ; Saenz CC
Int J Radiat Oncol Biol Phys; 2020 Aug; 107(5):964-973. PubMed ID: 32334034
[TBL] [Abstract][Full Text] [Related]
19. Single-photon emission computed tomography-defined active bone marrow-sparing volumetric-modulated arc therapy reduces the incidence of acute hematologic toxicity in locally advanced cervical cancer patients who receive chemoradiotherapy: A single-center prospective randomized controlled trial.
Wang S; Liu J; Lei K; Jia Y; Wang C; Zhang X; Li T
Cancer; 2023 Jul; 129(13):1995-2003. PubMed ID: 37043337
[TBL] [Abstract][Full Text] [Related]
20. Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin.
Lewis S; Chopra S; Naga P; Pant S; Dandpani E; Bharadwaj N; Mahantshetty U; Engineer R; Swamidas J; Ghosh J; Gupta S; Shrivastava S
Br J Radiol; 2018 Dec; 91(1092):20180005. PubMed ID: 30179056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]